Blueprint Medicines (NASDAQ:BPMC) Shares Down 1.6% – Should You Sell?

Shares of Blueprint Medicines Co. (NASDAQ:BPMC) dropped 1.6% during mid-day trading on Friday . The stock traded as low as $88.20 and last traded at $88.37. Approximately 55,876 shares changed hands during mid-day trading, a decline of 94% from the average daily volume of 1,000,307 shares. The stock had previously closed at $89.84.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. StockNews.com cut shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a research note on Monday, March 3rd. Guggenheim reissued a “buy” rating on shares of Blueprint Medicines in a research note on Wednesday, December 11th. Stephens reaffirmed an “overweight” rating and issued a $140.00 price objective on shares of Blueprint Medicines in a research note on Thursday, January 2nd. HC Wainwright reiterated a “buy” rating and issued a $135.00 price target on shares of Blueprint Medicines in a report on Friday, February 14th. Finally, Needham & Company LLC restated a “buy” rating and set a $133.00 price objective on shares of Blueprint Medicines in a report on Thursday, February 13th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $125.21.

Blueprint Medicines Trading Down 0.3 %

The stock has a 50-day simple moving average of $99.54 and a 200 day simple moving average of $94.03. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15. The company has a market cap of $5.72 billion, a price-to-earnings ratio of -82.94 and a beta of 0.58.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. As a group, equities research analysts predict that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

Insider Activity at Blueprint Medicines

In related news, CEO Kate Haviland sold 1,446 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total value of $159,407.04. Following the transaction, the chief executive officer now directly owns 149,378 shares in the company, valued at approximately $16,467,430.72. This represents a 0.96 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Christina Rossi sold 2,274 shares of the company’s stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $95.91, for a total value of $218,099.34. Following the transaction, the chief operating officer now owns 69,383 shares in the company, valued at $6,654,523.53. This trade represents a 3.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 46,608 shares of company stock worth $4,668,161 in the last 90 days. Corporate insiders own 4.21% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Empirical Asset Management LLC purchased a new stake in shares of Blueprint Medicines during the fourth quarter worth $2,348,000. Stephens Inc. AR purchased a new stake in Blueprint Medicines in the 4th quarter valued at approximately $321,000. Massachusetts Financial Services Co. MA boosted its holdings in Blueprint Medicines by 48.8% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 252,236 shares of the biotechnology company’s stock valued at $23,332,000 after purchasing an additional 82,693 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Blueprint Medicines by 2.4% during the 4th quarter. Bank of New York Mellon Corp now owns 303,432 shares of the biotechnology company’s stock valued at $26,465,000 after acquiring an additional 7,101 shares during the period. Finally, KBC Group NV lifted its position in shares of Blueprint Medicines by 63.9% during the 4th quarter. KBC Group NV now owns 2,625 shares of the biotechnology company’s stock valued at $229,000 after acquiring an additional 1,023 shares during the period.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.